17.43
price down icon2.30%   -0.41
after-market アフターアワーズ: 17.34 -0.09 -0.52%
loading
前日終値:
$17.84
開ける:
$17.85
24時間の取引高:
3.17M
Relative Volume:
0.50
時価総額:
$2.44B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-4.555
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
+3.01%
1か月 パフォーマンス:
+28.73%
6か月 パフォーマンス:
+72.06%
1年 パフォーマンス:
+70.05%
1日の値動き範囲:
Value
$16.85
$18.11
1週間の範囲:
Value
$16.17
$18.48
52週間の値動き範囲:
Value
$7.95
$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name
名前
Intellia Therapeutics Inc
Name
セクター
Healthcare (1094)
Name
電話
857-285-6200
Name
住所
40 ERIE STREET, CAMBRIDGE, MA
Name
職員
377
Name
Twitter
@intelliatweets
Name
次回の収益日
2026-08-06
Name
最新のSEC提出書
Name
NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NTLA icon
NTLA
Intellia Therapeutics Inc
17.43 2.49B 67.67M -412.69M -395.87M -3.8266
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
522.25 134.41B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
676.23 68.13B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
919.94 57.01B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
321.59 41.79B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
190.46 40.39B 742.00K -1.37B -1.07B -7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-02 アップグレード William Blair Mkt Perform → Outperform
2025-11-12 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-11 ダウングレード Evercore ISI Outperform → In-line
2025-11-07 ダウングレード JP Morgan Neutral → Underweight
2025-10-28 ダウングレード Bernstein Outperform → Mkt Perform
2025-10-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-10-27 ダウングレード Guggenheim Buy → Neutral
2025-10-27 ダウングレード William Blair Outperform → Mkt Perform
2025-10-06 アップグレード Citizens JMP Mkt Perform → Mkt Outperform
2025-04-21 アップグレード Wolfe Research Peer Perform → Outperform
2025-03-05 開始されました H.C. Wainwright Buy
2025-02-28 ダウングレード Goldman Neutral → Sell
2025-02-28 ダウングレード JP Morgan Overweight → Neutral
2025-01-27 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-23 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-04-13 開始されました Canaccord Genuity Buy
2023-03-21 開始されました Bernstein Outperform
2023-03-14 アップグレード BMO Capital Markets Market Perform → Outperform
2023-02-01 開始されました Cantor Fitzgerald Overweight
2023-01-24 アップグレード Citigroup Sell → Neutral
2023-01-19 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-21 開始されました JP Morgan Overweight
2022-09-01 開始されました Citigroup Sell
2022-06-17 開始されました BMO Capital Markets Market Perform
2022-06-16 開始されました BofA Securities Buy
2022-04-28 開始されました Credit Suisse Outperform
2022-02-18 開始されました William Blair Outperform
2022-02-07 アップグレード Oppenheimer Perform → Outperform
2022-01-31 開始されました Cowen Outperform
2022-01-07 開始されました Piper Sandler Overweight
2021-10-05 開始されました Guggenheim Buy
2021-09-24 開始されました Stifel Buy
2021-06-28 繰り返されました H.C. Wainwright Buy
2021-06-11 開始されました H.C. Wainwright Buy
2021-05-07 アップグレード ROTH Capital Neutral → Buy
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-03-04 開始されました JMP Securities Mkt Outperform
2020-12-22 ダウングレード Robert W. Baird Outperform → Neutral
2020-10-27 開始されました Truist Buy
2020-10-14 開始されました Wells Fargo Overweight
2020-09-18 開始されました Goldman Buy
2020-02-28 アップグレード Oppenheimer Perform → Outperform
2020-02-14 ダウングレード Wedbush Outperform → Neutral
2019-11-01 アップグレード Raymond James Mkt Perform → Outperform
2019-07-09 開始されました Robert W. Baird Outperform
2019-06-10 開始されました ROTH Capital Neutral
2019-05-03 アップグレード Wedbush Neutral → Outperform
2019-04-12 開始されました Evercore ISI Outperform
2018-11-02 ダウングレード Wedbush Outperform → Neutral
2018-10-29 開始されました Credit Suisse Neutral
2018-09-21 開始されました Raymond James Mkt Perform
2018-05-15 アップグレード Chardan Capital Markets Neutral → Buy
2018-03-08 開始されました JMP Securities Mkt Outperform
2017-11-01 繰り返されました Jefferies Buy
2017-06-22 再開されました Jefferies Buy
2017-03-28 開始されました Chardan Capital Markets Buy
2016-08-05 アップグレード Jefferies Hold → Buy
すべてを表示

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
Jul 06, 2026

Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dulac Edward J III - Moomoo

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock - Investing.com

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia CFO Edward Dulac III sells $84,186 in stock By Investing.com - Investing.com Australia

Jul 06, 2026
pulisher
Jul 06, 2026

Form 4 Intellia Therapeutics Inc For: 6 July By Investing.com - Investing.com Canada

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia Therapeutics (NTLA) VP sells shares to cover RSU tax - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia (NTLA) CFO’s 4,677-share sale executed under 10b5-1 plan - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 06, 2026
pulisher
Jul 06, 2026

Intellia lures 13 new employees with 53,250 stock awards - Stock Titan

Jul 06, 2026
pulisher
Jul 05, 2026

More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits

Jul 05, 2026
pulisher
Jul 05, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Jul 05, 2026
pulisher
Jul 05, 2026

NTLAIntellia Therapeutics Inc Forecast, Target Price - Finviz

Jul 05, 2026
pulisher
Jul 04, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Jul 04, 2026
pulisher
Jul 03, 2026

Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance

Jul 03, 2026
pulisher
Jul 02, 2026

Intellia Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo

Jul 02, 2026
pulisher
Jul 02, 2026

[144] Intellia Therapeutics, Inc. SEC Filing - Stock Titan

Jul 02, 2026
pulisher
Jul 01, 2026

NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jul 01, 2026
pulisher
Jul 01, 2026

Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Globe and Mail

Jul 01, 2026
pulisher
Jul 01, 2026

Investor Sentiment Divided in Healthcare Sector: Intellia Therap - GuruFocus

Jul 01, 2026
pulisher
Jul 01, 2026

Intellia Therapeutics (NASDAQ:NTLA): Can Innovation Justify the Buzz? - Kalkine Media

Jul 01, 2026
pulisher
Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to book forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to revenue forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – DUS:38I - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBIT forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Price to sales forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBITDA forward of Intellia Therapeutics, Inc. – NASDAQ:NTLA - TradingView

Jun 28, 2026
pulisher
Jun 27, 2026

Liquidity Mapping Around (NTLA) Price Events - Stock Traders Daily

Jun 27, 2026
pulisher
Jun 27, 2026

Certain Stock Options of Intellia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 28-JUN-2026. - marketscreener.com

Jun 27, 2026
pulisher
Jun 27, 2026

Price to earnings forward of Intellia Therapeutics, Inc. – BOATS:NTLA - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jun 27, 2026
pulisher
Jun 27, 2026

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Investors who Lost Money on Intellia Therapeutics, Inc. (NTLA) Sh - The National Law Review

Jun 27, 2026
pulisher
Jun 27, 2026

Intellia Therapeutics Inc (NTLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jun 27, 2026
pulisher
Jun 26, 2026

Intellia Therapeutics Stock Short Interest Rises to 45.4% - Moomoo

Jun 26, 2026
pulisher
Jun 26, 2026

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout | AI

Jun 26, 2026
pulisher
Jun 26, 2026

Intellia Therapeutics, Inc. Actuals & Estimates (NASDAQ:NTLA) - TradingView

Jun 26, 2026
pulisher
Jun 26, 2026

NTLA Stock Price, Quote & Chart - ChartMill

Jun 26, 2026
pulisher
Jun 25, 2026

Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors o - GuruFocus

Jun 25, 2026
pulisher
Jun 25, 2026

Intellia Therapeutics, Inc. Actuals & Estimates (SWB:38I) - TradingView

Jun 25, 2026
pulisher
Jun 25, 2026

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree - AOL.com

Jun 25, 2026
pulisher
Jun 25, 2026

Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Jun 2026 $NTLA - MarketBeat

Jun 25, 2026
pulisher
Jun 24, 2026

Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN

Jun 24, 2026
pulisher
Jun 24, 2026

Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why. - AOL.com

Jun 24, 2026

Intellia Therapeutics Inc (NTLA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Intellia Therapeutics Inc (NTLA) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Dulac Edward J III
EVP, Chief Financial Officer
Jul 02 '26
Sale
18.00
4,677
84,186
156,286
$112.84
price up icon 1.17%
$57.80
price up icon 1.55%
$36.31
price up icon 2.60%
$79.77
price down icon 2.48%
ONC ONC
$308.96
price down icon 0.16%
$190.46
price up icon 0.25%
大文字化:     |  ボリューム (24 時間):